This clinical trial is studying a new drug called ODM-212, which is being tested for treating certain advanced cancers. The study is in two parts: dose escalation and dose expansion/optimization. Part 1 is about finding the safest dose, and Part 2 is about seeing if it works well.

To join, you must be an adult (18+ years), able to take pills, and have a life expectancy of more than 12 weeks. You should have certain types of advanced cancer, like mesothelioma, pancreatic cancer, or a type of lung cancer with a specific mutation called KRAS G12C. You also should not have had certain treatments recently or have other serious health issues.

• The study involves two parts and may take several months.
• Participants should be prepared for regular visits and tests.
• Eligibility depends on specific cancer types and previous treatments.